Abstracts tagged "pregnancy"

Abstract Number: 1734 • 2012 ACR/ARHP Annual Meeting
Clinical Accuracy for Diagnosis of Antiphospholipid Syndrome in Systemic Lupus Erythematosus: Evaluation of 23 Possible Combinations of Antiphospholipid Antibody Specificities
Savino Sciascia¹, Veronica Murru¹, Giovanni Sanna², Dario Roccatello³, Munther A. Khamashta⁴ and Maria Laura Bertolaccini¹, ¹Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ²Louise Coote Lupus Unit, St. Thomas' Hospital, London, United Kingdom, ³Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ⁴Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom
Background/Purpose: The clinical accuracy of testing for antiphospholipid antibody (aPL) both, as individual tests and/or in combination, is still being investigated. We aimed to identify…
Abstract Number: 1735 • 2012 ACR/ARHP Annual Meeting
Independent Validation of the Antiphospholipid Score (aPL-S) for the Diagnosis of Antiphospholipid Syndrome (APS)
Savino Sciascia¹, Maria Laura Bertolaccini¹, Dario Roccatello² and Munther A. Khamashta³, ¹Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ²Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ³Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom
Background/Purpose: The so called “antiphospholipid score (aPL-S)” was recently developed and validated (1). This score was shown to be a useful quantitative index for diagnosing…
Abstract Number: 1423 • 2012 ACR/ARHP Annual Meeting
Vascular Thrombosis and Pregnancy Morbidity in Patients with Systemic Lupus Erythematosus with Positive Antiphospholipid Profile and Thrombocytopenia
Amir Haddad¹, Murray B. Urowitz², Dominique Ibanez² and D. D. Gladman³, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: The trigger for a thrombotic in patients with antiphospholipid antibodies is unknown. Thrombocytopenia is among the most common clinical manifestations of the Antiphospholipid antibody…
Abstract Number: 380 • 2012 ACR/ARHP Annual Meeting
DMARD and Biologic Use During Pregnancy Among Rheumatoid and Psoriatic Arthritis Patients in the Corrona Registry
John J. Cush¹, George Reed², Katherine C. Saunders³, Joel M. Kremer⁴, Jeffrey D. Greenberg⁵ and Arthur Kavanaugh⁶, ¹Baylor Research Institute, Dallas, TX, ²Division of Behavioral and Preventive Medicine, University of Massachusetts Medical School, Worcester, MA, ³Corrona, LLC., Southborough, MA, ⁴Center for Rheumatology, Albany Medical College, Albany, NY, ⁵Rheumatology, NYU Hospital for Joint Diseases, New York, NY, ⁶UCSD School of Medicine, La Jolla, CA
Background/Purpose: CORRONA is a nationwide longitudinal disease-based registry that includes 32875 rheumatoid (RA) and 5462 psoriatic arthritis (PsA) patients. We sought to ascertain the frequency…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].